poster abstractEmphymab™ Biotech was formed to develop and commercialize medical therapies that address serious lung diseases. The founders are scientists and clinicians at Indiana University School of Medicine. Emphymab’s lead technology is based on a novel monoclonal antibody that inactivates a newly discovered pathway involved in lung diseases and, thereby, halts progressive loss of lung function associated with emphysema. This technology has the potential to address the huge unmet medical need of patients suffering from chronic obstructive pulmonary disease (COPD) with emphysema, which is the 3rd leading cause of death worldwide
